Glenn Crater Selected Research

Chronic Obstructive Pulmonary Disease (COPD)

10/2019	Maintained therapeutic effect of revefenacin over 52 weeks in moderate to very severe Chronic Obstructive Pulmonary Disease (COPD).
10/2019	Data on the safety and tolerability of revefenacin, in patients with moderate to very severe chronic obstructive pulmonary disease.
4/2019	Improvements in Lung Function with Nebulized Revefenacin in the Treatment of Patients with Moderate to Very Severe COPD: Results from Two Replicate Phase III Clinical Trials.
1/2019	Cardiovascular safety of revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy of chronic obstructive pulmonary disease: Evaluation in phase 3 clinical trials.
1/2019	Revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy: Safety and tolerability results of a 52-week phase 3 trial in moderate to very severe chronic obstructive pulmonary disease.
12/2014	Effects of a combination of umeclidinium/vilanterol on exercise endurance in patients with chronic obstructive pulmonary disease: two randomized, double-blind clinical trials.
6/2014	Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials.
5/2014	Once-daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled study.
1/2014	Characterization of airway inflammation in patients with COPD using fractional exhaled nitric oxide levels: a pilot study.
7/2013	Safety, tolerability, pharmacokinetics and pharmacodynamics of single and repeat inhaled doses of umeclidinium in healthy subjects: two randomized studies.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Glenn Crater Research Topics

Disease

21	Chronic Obstructive Pulmonary Disease (COPD) 10/2019 - 08/2008
3	Dyspnea (Shortness of Breath) 05/2014 - 10/2009
2	Inflammation (Inflammations) 02/2016 - 01/2014
1	Albuminuria 01/2023
1	Diabetic Nephropathies (Diabetic Nephropathy) 01/2023
1	Fibrosis (Cirrhosis) 01/2023
1	Hyperplasia 01/2023
1	Polyuria 01/2023
1	Cardiovascular Diseases (Cardiovascular Disease) 01/2019
1	Atrial Fibrillation 01/2019
1	Asthma (Bronchial Asthma) 02/2016
1	Airway Obstruction (Choking) 11/2009
1	Cough 11/2009

Drug/Important Bio-Agent (IBA)

9	GSK573719IBA 12/2014 - 07/2012
8	Bronchodilator Agents (Bronchodilators)IBA 10/2019 - 11/2009
8	Muscarinic AntagonistsIBA 10/2019 - 10/2012
6	Tiotropium Bromide (Spiriva)FDA Link 10/2019 - 02/2012
5	revefenacinIBA 10/2019 - 01/2019
5	vilanterolIBA 12/2014 - 12/2012
4	Fluticasone-Salmeterol Drug Combination (Advair)FDA Link 02/2012 - 08/2008
3	Cholinergic Antagonists (Anticholinergics)IBA 01/2019 - 01/2012
3	Adrenal Cortex Hormones (Corticosteroids)IBA 02/2016 - 10/2009
3	Albuterol (Salbutamol)FDA LinkGeneric 05/2014 - 08/2008
3	Muscarinic Receptors (Muscarinic Acetylcholine Receptor)IBA 07/2013 - 07/2012
1	Urea (Carbamide)FDA LinkGeneric 01/2023
1	AlbuminsIBA 01/2023
1	Blood Glucose (Blood Sugar)IBA 01/2023
1	Genetic Markers (Genetic Marker)IBA 01/2023
1	Streptozocin (Streptozotocin)FDA Link 01/2023
1	Therapeutic UsesIBA 10/2019
1	SolutionsIBA 01/2019
1	omega-Chloroacetophenone (Mace)IBA 01/2019
1	Biomarkers (Surrogate Marker)IBA 02/2016
1	CytokinesIBA 02/2016
1	GoldIBA 01/2014
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 01/2014
1	Member 1 Subfamily B ATP Binding Cassette TransporterIBA 01/2013
1	Verapamil (Calan)FDA LinkGeneric 01/2013
1	Cytochrome P-450 CYP3A InhibitorsIBA 01/2013
1	Cytochrome P-450 CYP3AIBA 01/2013
1	insulin receptor-related receptor (IRR)IBA 01/2012
1	SmokeIBA 11/2009
1	Anti-Bacterial Agents (Antibiotics)IBA 10/2009
1	Ipratropium (Ipratropium Bromide)FDA LinkGeneric 08/2008

Therapy/Procedure

9	Therapeutics 10/2019 - 03/2011
1	Drug Therapy (Chemotherapy) 01/2012